Report: Last year's dealmaking boom will roll on into 2014

Biopharma's M&A rate jumped 11% in 2013 with the average deal value soaring 46%, according to PricewaterhouseCoopers, and analysts expect that healthy flow to continue into the new year. Year over year, transactions spiked 24% and dollar value doubled in the fourth quarter, according to PwC's numbers, driven by an increase in divestitures and a jump in valuations. Looking forward, macro-level trends, strong public markets and easy access to financing will keep the M&A train moving in 2014, PwC figures. More

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.